Requirements for global elimination of hepatitis B: a modelling study

The Lancet Infectious Diseases

Volumn 16, Issue 12, 2016, Pages 1399-1408

  Nayagam, Shevanthi ^a,b   Thursz, Mark ^a   Sicuri, Elisa ^b,c   Conteh, Lesong ^b   Wiktor, Stefan ^d   Low Beer, Daniel ^d   Hallett, Timothy B ^b  

^a ST MARY S HOSPITAL   (United Kingdom)

^b IMPERIAL COLLEGE LONDON   (United Kingdom)

^c CENTRE FOR RESEARCH IN ENVIRONMENTAL EPIDEMIOLOGY CREAL   (Spain)

^d WORLD HEALTH ORGANIZATION   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; ENTECAVIR; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B VACCINE; HEPATITIS B(E) ANTIGEN; TENOFOVIR;

ANTIVIRAL THERAPY; ARTICLE; CANCER MORTALITY; CHRONIC HEPATITIS B; DEMOGRAPHY; DISEASE CONTROL; HEALTH CARE ACCESS; HEALTH CARE COST; HEPATITIS B; HUMAN; LOW INCOME COUNTRY; MASS SCREENING; MEDICATION COMPLIANCE; MIDDLE INCOME COUNTRY; MORTALITY; PATIENT COMPLIANCE; PREVALENCE; PRIORITY JOURNAL; VACCINATION; VERTICAL TRANSMISSION; COMPLICATION; GLOBAL HEALTH; HEALTH CARE DELIVERY; INFANT; NEWBORN; PREVENTIVE HEALTH SERVICE; PROCEDURES; STATISTICAL MODEL;

ANTIVIRAL AGENTS; GLOBAL HEALTH; HEALTH SERVICES ACCESSIBILITY; HEPATITIS B; HEPATITIS B VACCINES; HUMANS; IMMUNIZATION PROGRAMS; INFANT; INFANT, NEWBORN; MASS SCREENING; MODELS, STATISTICAL; PREVALENCE; VACCINATION;

EID: 84994888125     PISSN: 14733099     EISSN: 14744457     Source Type: Journal    
DOI: 10.1016/S1473-3099(16)30204-3     Document Type: Article

References (45)

1. 1 World Health Assembly. Sixty-seventh World Health Assembly: agenda item 12.3 hepatitis, May 24, 2014, World Health Assembly, Geneva http://apps.who.int/gb/ebwha/pdf_files/WHA67/A67_R6-en.pdf (accessed Nov 9, 2015).
2. 2 Stanaway, JD, Flaxman, AD, Naghavi, M, et al. The global burden of viral hepatitis from 1990 to 2013: findings from the Global Burden of Disease Study 2013. Lancet, 2016 published online July 6. http://dx.doi.org/10.1016/S0140-6736(16)30579-7.
3. 3 GBD 2013 Mortality and Causes of Death Collaborators. Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet 385 (2015), 117–171.
4. 4 Thio, CL, Guo, N, Xie, C, Nelson, KE, Ehrhardt, S, Global elimination of mother-to-child transmission of hepatitis B: revisiting the current strategy. Lancet Infect Dis 15 (2015), 981–985.
5. 5 Andersson, MI, Rajbhandari, R, Kew, MC, et al. Mother-to-child transmission of hepatitis B virus in sub-Saharan Africa: time to act. Lancet Glob Health 3 (2015), e358–e359.
6. 6 Peto, TJ, Efficacy and effectiveness of infant vaccination against chronic hepatitis B in the Gambia Hepatitis Intervention Study (1986–90) and in the nationwide immunisation program. BMC Infect Dis, 4, 2014, 7.
7. 7 Chen, HL, Lin, LH, Hu, FC, et al. Effects of maternal screening and universal immunization to prevent mother-to-infant transmission of HBV. Gastroenterology, 142, 2012, 773 81.e2.
8. 8 Zhang, Z, Chen, C, Li, Z, Wu, Y-H, Xiao, X-M, Individualized management of pregnant women with high hepatitis B virus DNA levels. World J Gastroenterol 20 (2014), 12056–12061.
9. 9 Liaw, Y-F, Sung, J, Chow, W, et al. Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med 351 (2004), 1521–1531.
10. 10 Papatheodoridis, GV, Lampertico, P, Manolakopoulos, S, Lok, A, Incidence of hepatocellular carcinoma in chronic hepatitis B patients receiving nucleos(t)ide therapy: a systematic review. J Hepatol 53 (2010), 348–356.
11. 11 WHO, UNICEF. Estimates of national immunization coverage, 2014, World Health Organization, Geneva http://apps.who.int/immunization_monitoring/globalsummary/timeseries/tscoveragehepb_bd.html (accessed Feb 2, 2015).
12. 12 WHO. Global policy report on the prevention and control of viral hepatitis in WHO Member States, 2013, World Health Organization, Geneva http://www.who.int/hepatitis/publications/global_report/en/ (accessed Aug 1, 2016).
13. 13 Ott, JJ, Stevens, GA, Groeger, J, Wiersma, ST, Global epidemiology of hepatitis B virus infection: new estimates of age-specific HBsAg seroprevalence and endemicity. Vaccine 30 (2012), 2212–2219.
14. 14 Ott, JJ, Stevens, GA, Wiersma, ST, The risk of perinatal hepatitis B virus transmission: hepatitis B e antigen (HBeAg) prevalence estimates for all world regions. BMC Infect Dis, 12, 2012, 131.
15. 15 International Agency for Research on Cancer, WHO. GLOBOCAN 2012: Estimated cancer incidence, mortality and prevalence worldwide in 2012. http://globocan.iarc.fr/Pages/online.aspx (accessed Dec 13, 2014).
16. 16 UN Department of Economic and Social Affairs, Population Division. World Population Prospects: the 2012 revision. http://esa.un.org/unpd/wpp/ (accessed Dec 5, 2014).
17. 17 Lok, A, McMahon, B, Chronic hepatitis B. Hepatology 45 (2007), 507–539.
18. 18 European Association For The Study Of The Liver. EASL Clinical Practice Guidelines: management of chronic hepatitis B. J Hepatol 50 (2009), 227–242.
19. 19 WHO. Guidelines for the prevention, care and treatment of persons with chronic hepatitis B infection, 2015, World Health Organization, Geneva http://www.who.int/hiv/pub/hepatitis/hepatitis-b-guidelines/en/ (accessed Nov 9, 2015).
20. 20 WHO. WHO guide for standardization of economic evaluations of immunization programmes, 2008, World Health Organization, Geneva http://apps.who.int/iris/handle/10665/69981 (accessed Nov 9, 2015).
21. 21 WHO. Global Vaccine Action Plan 2011–2020, 2013, World Health Organization, Geneva http://www.who.int/immunization/global_vaccine_action_plan/GVAP_doc_2011_2020/en/ (accessed Nov 9, 2015).
22. 22 WHO, The World Bank. Monitoring progress towards universal health coverage at country and global level: framework, measures and targets, 2014, World Health Organization, Geneva http://apps.who.int/iris/bitstream/10665/112824/1/WHO_HIS_HIA_14.1_eng.pdf (accessed Nov 19, 2015).
23. 23 Mackie, CO, Buxton, JA, Tadwalkar, S, Patrick, DM, Hepatitis B immunization strategies: timing is everything. CMAJ 180 (2009), 196–202.
24. 24 Beasley, RP, Hwang, LY, Lee, GC, et al. Prevention of perinatally transmitted hepatitis B virus infections with hepatitis B immune globulin and hepatitis B vaccine. Lancet 2 (1983), 1099–1102.
25. 25 Lee, C, Gong, Y, Brok, J, Boxall, E, Gluud, C, Effect of hepatitis B immunisation in newborn infants of mothers positive for hepatitis B surface antigen: systematic review and meta-analysis. BMJ 332 (2006), 328–336.
26. 26 Xu, Z-Y, Liu, C-B, Francis, DP, et al. Prevention of perinatal acquisition of hepatitis B virus carriage using vaccine: preliminary report of a randomized, double-blind placebo-controlled and comparative trial. Pediatrics 76 (1985), 713–718.
27. 27 Beasley, RP, Trepo, C, Stevens, C, Szmuness, W, The e antigen and vertical transmission of hepatitis B surface antigen. Am J Epidemiol 105 (1977), 94–98.
28. 28 Wong, VC, Ip, HM, Reesink, HW, et al. Prevention of the HBsAg carrier state in newborn infants of mothers who are chronic carriers of HBsAg and HBeAg by administration of hepatitis-B vaccine and hepatitis-B immunoglobulin. Double-blind randomised placebo-controlled study. Lancet 1 (1984), 921–926.
29. 29 Schweitzer, A, Horn, J, Mikolajczyk, RT, Krause, G, Ott, JJ, Estimations of worldwide prevalence of chronic hepatitis B virus infection: a systematic review of data published between 1965 and 2013. Lancet 386 (2015), 1546–1555.
30. 30 World Bank. Country and lending groups. http://data.worldbank.org/about/country-and-lending-groups (accessed Nov 5, 2015).
31. 31 UNAIDS. 2013 Report on the global AIDS epidemic, 2013, Joint United Nations Programme on HIV/AIDS, Geneva http://www.unaids.org/en/resources/campaigns/globalreport2013/globalreport (accessed Nov 9, 2015).
32. 32 Xu, K, Evans, DB, Kawabata, K, Zeramdini, R, Klavus, J, Murray, CJL, Household catastrophic health expenditure: a multicountry analysis. Lancet 362 (2003), 111–117.
33. 33 Lu, J, Xu, A, Wang, J, et al. Direct economic burden of hepatitis B virus related diseases: evidence from Shandong, China. BMC Health Serv Res, 13, 2013, 37.
34. 34 Piot, P, Abdool Karim, SS, Hecht, R, et al. Defeating AIDS—advancing global health. Lancet 386 (2015), 171–218.
35. 35 UNAIDS. Fast track: ending the AIDS epidemic by 2030, 2014, Joint United Nations Programme on HIV/AIDS, Geneva http://www.unaids.org/en/resources/documents/2014/JC2686_WAD2014report (accessed Nov 9, 2015).
36. 36 WHO. Global Health Observatory data repository: maternal and reproductive health. http://apps.who.int/gho/data/view.main.1610?lang=en (accessed Sept 1, 2015).
37. 37 Lemoine, M, Shimakawa, Y, Njie, R, et al. Acceptability and feasibility of a screen-and-treat programme for hepatitis B virus infection in The Gambia: the Prevention of Liver Fibrosis and Cancer in Africa (PROLIFICA) study. Lancet Glob Health 4 (2016), e559–e567.
38. 38 Nayagam, S, Conteh, L, Sicuri, E, et al. Cost-effectiveness of community-based screening and treatment for chronic hepatitis B in The Gambia: an economic modelling analysis. Lancet Glob Health 4 (2016), e568–e578.
39. 39 Zeisel, MB, Lucifora, J, Mason, WS, et al. Towards an HBV cure: state-of-the-art and unresolved questions—report of the ANRS workshop on HBV cure. Gut 64 (2015), 1314–1326.
40. 40 Goldstein, ST, Zhou, F, Hadler, SC, Bell, BP, Mast, EE, Margolis, HS, A mathematical model to estimate global hepatitis B disease burden and vaccination impact. Int J Epidemiol 34 (2005), 1329–1339.
41. 41 Edmunds, WJ, Epidemiological patterns of hepatitis B virus (HBV) in highly endemic areas. Epidemiol Infect 117 (1996), 313–325.
42. 42 Williams, JR, Nokes, DJ, Medley, GF, Anderson, RM, The transmission dynamics of hepatitis B in the UK: a mathematical model for evaluating costs and effectiveness of immunization programmes. Epidemiol Infect 116 (1996), 71–89.
43. 43 Kretzschmar, M, Mangen, M-J, van de Laar, M, de Wit, A, Model based analysis of hepatitis B vaccination strategies in the Netherlands. Vaccine 27 (2009), 1254–1260.
44. 44 Parkin, DM, The evolution of the population-based cancer registry. Nat Rev Cancer 6 (2006), 603–612.
45. 45 Shimakawa, Y, Bottomley, C, Njie, R, Mendy, M, The association between maternal hepatitis B e antigen status, as a proxy for perinatal transmission, and the risk of hepatitis B e antigenaemia in Gambian children. BMC Public Health, 14, 2014, 532.